Ocular Inflammation

22
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
19
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
19
Early DiscoveryClinical DevelopmentMarket

On Market (19)

Approved therapies currently available

U
ACTICORTApproved
hydrocortisone
Unknown Company
topical1981
U
ALA-CORTApproved
hydrocortisone
Unknown Company
topical1973
U
ALKINDI SPRINKLEApproved
hydrocortisone
Unknown Company
Corticosteroid [EPC]oral2020
Bausch + Lomb
ALREXApproved
loteprednol etabonate
Bausch + Lomb
ophthalmic1998
U
BALNEOL-HCApproved
hydrocortisone
Unknown Company
topical1982
U
BETA-HCApproved
hydrocortisone
Unknown Company
topical1988
U
DERMACORTApproved
hydrocortisone
Unknown Company
topical
U
EPICORTApproved
hydrocortisone
Unknown Company
topical
U
FLEXICORTApproved
hydrocortisone
Unknown Company
topical
U
GLYCORTApproved
hydrocortisone
Unknown Company
topical1983
U
HC (HYDROCORTISONE)Approved
hydrocortisone
Unknown Company
topical1973
U
HI-CORApproved
hydrocortisone
Unknown Company
topical1973
U
HYDRO-RXApproved
hydrocortisone
Unknown Company
for rx compounding1978
U
HYTONEApproved
hydrocortisone
Unknown Company
topical1972
U
KHINDIVIApproved
hydrocortisone
Unknown Company
Corticosteroid [EPC]oral2025
U
LOTEMAXApproved
loteprednol etabonate
Unknown Company
ophthalmic1998
Bausch + Lomb
LOTEMAX SMApproved
loteprednol etabonate
Bausch + Lomb
ophthalmic2019
U
LOTEPREDNOL ETABONATEApproved
loteprednol etabonate
Unknown Company
ophthalmic2025
U
NOGENIC HCApproved
hydrocortisone
Unknown Company
topical1988

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
2
1
0.5% Loteprednol Etabonate Ophthalmic OintmentPhase 31 trial
Loteprednol EtabonatePhase 31 trial
Active Trials
NCT00645671Completed400Est. Mar 2009
NCT00699153Completed400Est. Jun 2009
Thea Pharma
Thea PharmaMA - Waltham
1 program
1
HydrocortisonePhase 31 trial
Active Trials
NCT05668455RecruitingEst. Jul 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Thea PharmaHydrocortisone
Bausch + LombLoteprednol Etabonate
Bausch + Lomb0.5% Loteprednol Etabonate Ophthalmic Ointment

Clinical Trials (3)

Total enrollment: 800 patients across 3 trials

NCT05668455Thea PharmaHydrocortisone

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Start: May 2023Est. completion: Jul 2026
Phase 3Recruiting
NCT00699153Bausch + LombLoteprednol Etabonate

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

Start: Jun 2008Est. completion: Jun 2009400 patients
Phase 3Completed
NCT00645671Bausch + Lomb0.5% Loteprednol Etabonate Ophthalmic Ointment

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

Start: Mar 2008Est. completion: Mar 2009400 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 800 patients
2 companies competing in this space